Librela
ليبريلا
Librela (bedinvetmab) is the first and only canine monoclonal antibody therapy targeting Nerve Growth Factor (NGF) for the alleviation of pain associated with osteoarthritis (OA) in dogs, providing once-monthly pain relief.
Dosage Form
Injection
Product Type
Biological
Manufacturer
Package
Vials containing 5 mg, 10 mg, 15 mg, 20 mg, or 30 mg bedinvetmab in 1 mL aqueous solution (packs of 2 vials)
Dosages
| Species | Dosage | Route | Duration |
|---|---|---|---|
| Dog | 0.5 – 1.0 mg/kg body weight based on dosing table | Subcutaneous (SC) | Once monthly (every 28 days) |
Withdrawal Periods
No withdrawal information available.
Indications
-
Control and alleviation of pain associated with osteoarthritis in dogs.
Contraindications
-
Do not use in dogs with known hypersensitivity to bedinvetmab.
-
Do not use in breeding, pregnant, or lactating dogs.
-
Do not use in dogs under 12 months of age.
Precautions
-
Bedinvetmab may cross the placental barrier and be excreted in milk; therefore do not use in breeding animals.
-
Monoclonal antibodies are eliminated via normal cellular catabolism with minimal involvement of renal or hepatic pathways.
-
Transient pain at the injection site may be observed.
Side Effects
-
Mild swelling at the injection site, urinary tract infections, increased blood urea nitrogen (BUN), dermatitis, and lameness.
Images
Documents
-
Download
Librela Prescribing Information
Leaflet
Active Ingredients
-
Bedinvetmab
5 mg/mL (5, 10, 15, 20, 30 mg)
Diseases
No diseases linked.
Related Products
No data available
Information has not been added yet.
Related Products By Active Ingredient
No data available
Information has not been added yet.
Companies
-
Zoetis
Manufacturer
Alternatives
No alternatives available.